Dataset: Significant Effects of Antiretroviral Therapy on Global Gene Expression in Brain Tissues of Patients with HIV-Associated Neurocognitive Disorders
Antiretroviral therapy (ART) has reduced morbidity and mortality in HIV infection; however HIV-1-associated neurocognitive disorders...
Antiretroviral therapy (ART) has reduced morbidity and mortality in HIV infection; however HIV-1-associated neurocognitive disorders (HAND) persist despite treatment. We used microarray analysis in post-mortem brain tissues to determine ART effectiveness in the brain and to identify molecular signatures of HAND under ART. We performed microarray analysis using Affymetrix Arrays in portmortem brain tissues from seven treated and eight untreated HAND patients and six uninfected controls.
- Species:
- human
- Samples:
- 35
- Source:
- E-GEOD-28160
- Updated:
- Dec.12, 2014
- Registered:
- Sep.15, 2014
Factors:
(via ArrayExpress)
Sample | DISEASE STATE | TREATMENT |
---|---|---|
GSM697483 | uninfected | untreated |
GSM697483 | uninfected | untreated |
GSM697483 | uninfected | untreated |
GSM697483 | uninfected | untreated |
GSM697483 | uninfected | untreated |
GSM697483 | uninfected | untreated |
GSM697483 | uninfected | untreated |
GSM697483 | uninfected | untreated |
GSM697483 | uninfected | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697492 | HIV1 with HIV-1-associated neurocognitive disorders | untreated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |
GSM697506 | HIV1 with HIV-1-associated neurocognitive disorders | antiretroviral treated |